CLPH-511 (Cryopreserved Platelets)
Bleeding in thrombocytopenia/platelet dysfunction (e.g., cardiac surgery, trauma)
Key Facts
About Cellphire Therapeutics
Cellphire Therapeutics is pioneering the development of stabilized platelet biologics to solve critical shortages and logistical challenges associated with traditional platelet transfusions. The company has two primary clinical-stage assets: CLPH-511 (cryopreserved platelets) and the FPH platform (freeze-dried platelet-derived hemostats like Thrombosomes®), both in Phase 2 studies for acute bleeding. Its first commercial product, StablePlate RX® Canine, is marketed through its veterinary subsidiary, BodeVet®, providing an early revenue stream. Cellphire aims to address a significant unmet need in both military and civilian settings where hemorrhage is a leading cause of preventable death.
View full company profile